Citizens Reiterates Market Outperform on Kura Oncology, Maintains $24 Price Target

Benzinga Newsdesk www.benzinga.com Negative 93.2%

Neg 93.2% Neu 0% Pos 0%

Citizens analyst Reni J. Benjamin reiterates Kura Oncology (NASDAQ:KURA) with a Market Outperform and maintains $24 price target.